Drug Profile
Research programme: anti-ischaemic therapeutics - Quantum Genomics
Alternative Names: QGC 002Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator INSERM
- Class Recombinant proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Ischaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Ischaemia in France (Parenteral)
- 25 Jan 2008 Preclinical trials in Ischaemia in France (Parenteral)